ReviewWorld journal of gastroenterology2023
Autoimmune liver diseases and SARS-CoV-2.
Review in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Experimental intranasal infection reveals broad tissue tropism of bovine coronavirus.Veterinary research · 2026Article
- Temporal changes in etiology, complications, and infection-related admissions among patients with cirrhosis: a 20-year single-center study.Frontiers in medicine · 2026Article
- Post-COVID-19 Pandemic Sequelae in Liver Diseases.Life (Basel, Switzerland) · 2025Review
- A Closer Look into Autoimmune Liver Diseases.International journal of molecular sciences · 2025Review
- New onset autoimmune disease following a SARS-CoV-2 infection: A systematic review protocol.PloS one · 2025Article
- Simultaneous occurrence of autoimmune hepatitis and autoimmune hemolytic anemia after COVID-19 infection: case report and literature review.Clinical journal of gastroenterology · 2024Review
- Review
- Histopathological impact of SARS-CoV-2 on the liver: Cellular damage and long-term complications.World journal of gastroenterology · 2024Review
- Article
- Editor-in-Chief articles of choice and comments at the year-end of 2023.World journal of gastroenterology · 2024Article
- SARS-CoV-2 Vaccination Response in Japanese Patients with Autoimmune Hepatitis: Results of Propensity Score-Matched Case-Control Study.Journal of clinical medicine · 2023Article
- Unraveling the Molecular and Cellular Pathogenesis of COVID-19-Associated Liver Injury.Viruses · 2023Review
- Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), can trigger autoimmunity in genetically predisposed individuals through hyperstimulation of immune response and molecular mimicry. Here we summarise the current knowledge about auto-immune liver diseases (AILDs) and SARS-CoV-2, focusing on: (1) The risk of SARS-CoV-2 infection and the course of COVID-19 in patients affected by AILDs; (2) the role of SARS-CoV-2 in inducing liver damage and triggering AILDs; and (3) the ability of vaccines against SARS-CoV-2 to induce autoimmune responses in the liver. Data derived from the literature suggest that patients with AILDs do not carry an increased risk of SARS-Cov-2 infection but may develop a more severe course of COVID-19 if on treatment with steroids or thiopurine. Although SARS-CoV-2 infection can lead to the development of several autoimmune diseases, few reports correlate it to the appearance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.